DDO-2093

N/A

Report date: 2022/06/29 15:08:16
NME

Base Information

Drug NameDDO-2093
Drug Alias NameDDO-2093
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionWD repeat-containing protein 5 inhibitorsHistone-lysine N-methyltransferase 2A inhibitors
TargetsWD repeat-containing protein 5Histone-lysine N-methyltransferase 2A
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesChina Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A